Expert perspectives on historical and novel treatment strategies for patients diagnosed with chronic graft-versus-host disease.
EP. 1: Background on Graft-vs-Host Disease: Risk Factors and Prevention
EP. 2: Acute vs Chronic GVHD: Identification and Stratification
EP. 3: Frontline Treatment Options for Chronic GVHD
EP. 4: Defining Steroid-Refractory and Steroid-Dependent GVHD
EP. 5: Identifying and Managing Steroid-Refractory Chronic GVHD
EP. 6: Ibrutinib’s Approval and Use in Chronic Graft-Versus-Host Disease
EP. 7: Belumosudil’s Approval and Use in Chronic Graft-Vs-Host Disease
EP. 8: Mechanism of Action of Ruxolitinib
EP. 9: REACH3 Trial: Approval of Ruxolitinib in Chronic GVHD
EP. 10: Chronic GVHD: Real-World Use of Ruxolitinib
EP. 11: Selecting Second-Line Therapy for Chronic GVHD
EP. 12: Chronic GVHD: Novel Treatment Approaches With Approved Agents
EP. 13: Novel Targeted Agents in GVHD: The FLIGHT and AGAVE-201 Trials
EP. 14: HSCT Approaches to Retain GVL While Preventing GVHD
EP. 15: Emerging Treatment Strategies for Chronic GVHD
Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies
Pelabresib/Ruxolitinib Combo Improves Splenomegaly, TSS in JAK Inhibitor–Naive Myelofibrosis
Tisagenlecleucel Yields Durable Responses in R/R Follicular Lymphoma
Ruxolitinib Shows Sustained Efficacy Over Best Available Therapy in Steroid-Refractory/Dependent cGVHD